Table of contentsP001 - Sepsis impairs the capillary response within hypoxic capillaries and decreases erythrocyte oxygen-dependent ATP effluxR. M. Bateman, M. D. Sharpe, J. E. Jagger, C. G. EllisP002 - Lower serum immunoglobulin G2 level does not predispose to severe flu.J. Solé-Violán, M. López-Rodríguez, E. Herrera-Ramos, J. Ruíz-Hernández, L. Borderías, J. Horcajada, N. González-Quevedo, O. Rajas, M. Briones, F. Rodríguez de Castro, C. Rodríguez GallegoP003 - Brain protective effects of intravenous immunoglobulin through inhibition of complement activation and apoptosis in a rat model of sepsisF. Esen, G. Orhun, P. Ergin Ozcan, E. Senturk, C. Ugur Yilmaz, N. Orhan, N. Arican, M. Kaya, M. Kucukerden, M. Giris, U. Akcan, S. Bilgic Gazioglu, E. TuzunP004 - Adenosine a1 receptor dysfunction is associated with leukopenia: A possible mechanism for sepsis-induced leukopeniaR. Riff, O. Naamani, A. DouvdevaniP005 - Analysis of neutrophil by hyper spectral imaging - A preliminary reportR. Takegawa, H. Yoshida, T. Hirose, N. Yamamoto, H. Hagiya, M. Ojima, Y. Akeda, O. Tasaki, K. Tomono, T. ShimazuP006 - Chemiluminescent intensity assessed by eaa predicts the incidence of postoperative infectious complications following gastrointestinal surgeryS. Ono, T. Kubo, S. Suda, T. Ueno, T. IkedaP007 - Serial change of c1 inhibitor in patients with sepsis – A prospective observational studyT. Hirose, H. Ogura, H. Takahashi, M. Ojima, J. Kang, Y. Nakamura, T. Kojima, T. ShimazuP008 - Comparison of bacteremia and sepsis on sepsis related biomarkersT. Ikeda, S. Suda, Y. Izutani, T. Ueno, S. OnoP009 - The changes of procalcitonin levels in critical patients with abdominal septic shock during blood purificationT. Taniguchi, M. OP010 - Validation of a new sensitive point of care device for rapid measurement of procalcitoninC. Dinter, J. Lotz, B. Eilers, C. Wissmann, R. LottP011 - Infection biomarkers in primary care patients with acute respiratory tract infections – Comparison of procalcitonin and C-reactive proteinM. M. Meili, P. S. SchuetzP012 - Do we need a lower procalcitonin cut off?H. Hawa, M. Sharshir, M. Aburageila, N. SalahuddinP013 - The predictive role of C-reactive protein and procalcitonin biomarkers in central nervous system infections with extensively drug resistant bacteriaV. Chantziara, S. Georgiou, A. Tsimogianni, P. Alexandropoulos, A. Vassi, F. Lagiou, M. Valta, G. Micha, E. Chinou, G. MichaloudisP014 - Changes in endotoxin activity assay and procalcitonin levels after direct hemoperfusion with polymyxin-b immobilized fiberA. Kodaira, T. Ikeda, S. Ono, T. Ueno, S. Suda, Y. Izutani, H. ImaizumiP015 - Diagnostic usefullness of combination biomarkers on ICU admissionM. V. De la Torre-Prados, A. Garcia-De la Torre, A. Enguix-Armada, A. Puerto-Morlan, V. Perez-Valero, A. Garcia-AlcantaraP016 - Platelet function analysis utilising the PFA-100 does not predict infection, bacteraemia, sepsis or outcome in critically ill patientsN. Bolton, J. Dudziak, S. Bonney, A. Tridente, P. NeeP017 - Extracellular histone H3 levels are in...
PURPOSE: Currently venous thromboembolism (VTE) is still considered a common preventable condition in hospitalized patients. However a significant proportion of VTE cases occur in patients who have received appropriate prophylactic measures according to the current guidelines. Financial implications for healthcare institutions for quality performance and costs incurred from the event can be substantial. We propose a classification system for preventable VTE versus non-preventable VTE cases based on compliance with appropriate prophylaxis based on current evidenced based guidelines. METHODS: Patients with hospital acquired VTE were identified in an academic tertiary care center. 120 cases during January 2015 to February 2016 were randomly selected for analysis for adherence to VTE prophylaxis guidelines. VTE prophylaxis compliance was based on American College of Chest Physicians 9th edition (ACCP) guidelines. Prescription order compliance was defined by appropriate pharmacological and/or mechanical prophylaxis being prescribed for the patient if indicated. Mechanical prophylaxis compliance was defined as appropriate adherence to mechanical prophylaxis during the indicated period. Pharmacological prophylaxis compliance was defined as appropriate dosing being administered during the indicated period. If there was full compliance with the measures, then health care delivery was termed as 'optimal' or defect-free. If any hospitalized patients develop VTE despite optimal care, it was classified as potentially non-preventable VTE. If any lapse in adherence to the guidelines was identified, it was termed as 'sub-optimal' care. The VTE cases resulting from sub-optimal care were classified as potentially preventable. An algorithm for classification of Hospital Acquired VTEs was developed using the above defined compliance measures. RESULTS: One hundred and twenty hospital acquired venous thromboembolism events were analyzed. 42 of 120 (35%) VTE cases are potentially preventable and 78 of 120 (65%) are potentially non-preventable. Pharmacological prophylaxis was ordered in 97.5% and mechanical prophylaxis was ordered in 89.16% prior to the development of VTE. Gap in pharmacological prophylaxis was found in 16 cases (13.33%), 15 cases (12.5%) had gap in mechanical prophylaxis and gaps in pharmacological and mechanical prophylaxis was found in 11 cases (9.12%). CONCLUSIONS: Majority (65%) of hospital acquired VTEs are Non-Preventable based on compliance with the 9th edition ACCP Guidelines for VTE prevention. CLINICAL IMPLICATIONS: Quality performance measures should target preventable VTE events rather than all hospital acquired VTE episodes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.